We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 162.73 | 299 | 10:25:17 |
From May 2019 to May 2024
By Michael Dabaie
Dragonfly Therapeutics said it is in a collaboration with AbbVie Inc. (ABBV).
The biopharmaceutical company said it and AbbVie are in a multi-target research collaboration designed to advance Dragonfly's immunotherapies for autoimmune and oncology indications.
The deal grants AbbVie the option to license exclusive worldwide intellectual property rights to develop and commercialize products directed to specific targets using Dragonfly's TriNKET technology platform.
AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties, Dragonfly said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 20, 2019 09:29 ET (14:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
